Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalyst Pharm Inc (NQ: CPRX )

14.01 -0.24 (-1.68%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,046,003
Open 14.27
Bid (Size) 13.80 (3)
Ask (Size) 14.01 (3)
Prev. Close 14.25
Today's Range 13.87 - 14.39
52wk Range 11.09 - 22.11
Shares Outstanding 102,780,151
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap Companies
Catalyst Ranked #4 on the List 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
-22.43%
-22.43%
1 Month
+7.85%
+7.85%
3 Month
+8.27%
+8.27%
6 Month
+16.17%
+16.17%
1 Year
-17.49%
-17.49%

More News

Read More
Catalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Recap: Catalyst Pharmaceuticals Q3 Earnings
Via Benzinga
Why the growth investor may take a look at NASDAQ:CPRX.
Via Chartmill
5 Analysts Have This to Say About Catalyst Pharmaceuticals
Via Benzinga
Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
3 Robinhood Stocks to Buy Right Now
Via The Motley Fool
Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Partners with Sofie's Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education Expo
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 8, 2023
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Patrick J. McEnany, Chairman and CEO of Catalyst Pharmaceuticals, Receives Prestigious 2023 Lifetime Achievement Award from BioFlorida
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
2 Robinhood Stocks With Market-Beating Potential
Via The Motley Fool
Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSE®
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
10 Best Defensive Stocks To Invest In 2023
Via Talk Markets
Topics Economy
Exposures Economy
Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Vertex Pharmaceuticals Stock Shows Rising Relative Strength, Hits 80+
Via Investor's Business Daily
Catalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
ACELYRIN Stock Scores Relative Strength Rating Upgrade; Hits Key Threshold
Via Investor's Business Daily
Axsome Therapeutics Stock Earns Relative Strength Rating Upgrade
Via Investor's Business Daily
Exelixis Stock Sees Rising Relative Strength Rating
Via Investor's Business Daily
Catalyst Pharmaceuticals Announces Multiple Abstracts on FYCOMPA® (Perampanel) from Eisai Co, Ltd., to be Presented at the 35th International Epilepsy Congress
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.